In a clinical investigation evaluating airway defense mechanisms, researchers discovered that individuals with Progressive Supranuclear Palsy cannot volitionally suppress reflexive cough, demonstrating identical sensory and motor response thresholds whether coughing naturally or attempting conscious suppression. Progressive Supranuclear Palsy is a rare neurodegenerative tauopathy that disrupts normal neural and glial function across the basal ganglia, frontal cortex, pontine structures, and white matter pathways. Because effective cough clears the respiratory tract and supports ventilation, impaired cough function frequently causes severe pulmonary compromise and fatal lung infections, which represent a leading cause of death in this population. Clinical identification of Progressive Supranuclear Palsy remains challenging because its symptoms closely mimic Parkinson disease and Multiple System Atrophy. By testing reflexive cough under both natural and actively suppressed conditions, investigators aimed to clarify how neuropathology impacts cortical modulation over vital airway protection.
Human airway protection depends on multiple cough modalities categorized into spontaneous-reflex, induced-reflex, and voluntary cough. Spontaneous-reflex cough occurs naturally when environmental particulates, aspirate material, or retained mucus stimulate airway receptors to trigger an immediate protective expulsive response. Induced-reflex cough is evoked experimentally when controlled concentrations of chemical stimuli, including capsaicin, citric acid, tartaric acid, or distilled water, are inhaled specifically to analyze sensorimotor responsiveness. In contrast, voluntary cough is initiated deliberately without a peripheral sensory stimulus, relying on complex cortical motor planning and programming. Even during induced-reflex challenges, a meaningful degree of volitional control persists through cortical activation. This capacity to modulate reflexive cough is governed by motivation and the urge-to-cough, which represents the cortical perception of airway irritation. The urge-to-cough integrates emotional, motivational, localization, and sensory processing, determining whether an individual will suppress, facilitate, or modify motor output based on environmental and physical context.
Volitional cough suppression can be evaluated through experimental protocols requiring individuals to consciously inhibit coughing after inhaling progressive doses of a cough stimulus. Prior research by Leow and colleagues demonstrated that healthy young adults, healthy older adults, and patients with Parkinson disease all exhibit significantly higher cough thresholds during suppression testing compared to natural testing when challenged with citric acid. Although patients with Parkinson disease demonstrated a smaller suppression capacity than healthy peers, they still achieved suppression until stimulus concentrations rose one to two levels above baseline. Furthermore, research by Borders and colleagues established that while some individuals with Progressive Supranuclear Palsy could not initiate voluntary cough on command, they successfully upregulated cough airflow when presented with capsaicin combined with visual and auditory cues. However, prior to this investigation, researchers had not evaluated whether individuals with Progressive Supranuclear Palsy retain the capacity to downregulate or suppress reflexive cough responses.
To investigate this question, the researchers conducted a pilot study examining thirteen individuals diagnosed with Progressive Supranuclear Palsy who were recruited from a movement disorders clinic between November 2021 and March 2022. The participant cohort consisted of seven men and six women with a mean age of 70.85 years and an age range spanning 61 to 81 years. Eleven participants presented with the Progressive Supranuclear Palsy-Richardson Syndrome phenotype, while one participant had the Speech-Language variant and another presented with Progressive Gait Freezing. The average duration from formal diagnosis was 1.92 years, with an observed range from 0.5 to 4.0 years, while the average duration since symptom onset was 4.44 years, ranging from 2.75 to 8.0 years. Cognitive evaluation via the Montreal Cognitive Assessment revealed a cohort mean score of 25.92 across a range of 24 to 28. In addition, the mean Beck Depression Inventory-II score was 11, ranging between 1 and 17.
Enrollment followed specific diagnostic and safety criteria to guarantee precise clinical categorization and participant safety. All participants had a clinical diagnosis of possible or probable Progressive Supranuclear Palsy provided by fellowship-trained movement disorder neurologists using the Hoglinger diagnostic framework. Participants were enrolled after providing verbal and written informed consent under institutional review board approval, with study procedures conducted in accordance with the Declaration of Helsinki. Candidates were excluded if they possessed any other neurological diagnosis, scored below 20 on the Montreal Cognitive Assessment, or presented severe depressive risk on the Beck Depression Inventory-II. The study also excluded individuals unable to ambulate at least ten feet with or without assistance, those with disease duration exceeding five years, and anyone with a capsaicin allergy. Additional exclusion criteria included any history of head, neck, or lung cancer, current respiratory infection, chronic respiratory disease, or cigarette smoking within the past five years.
Airflow, volume, and aerosol delivery were measured using an integrated physiological testing setup. Spirometry volume calibration was established with a three-liter syringe prior to testing. Participants breathed through a disposable Ambu facemask attached to an ADInstruments MLT1000L pneumotachograph, which was coupled to an ADInstruments FE141 differential pressure transducer to record respiratory airflow and volume signals in LabChart8 software. Participants completed at least one minute of quiet baseline breathing to acclimate to the apparatus. Cough stimuli were aerosolized using a PulmoMate compressor linked to a DeVilbiss Model 646 nebulizer positioned in the inspiratory limb of the circuit. A KoKo Ferraris dosimeter delivered stimulus aerosols at five liters per minute across a two-second activation window triggered immediately upon participant inspiration. This system enabled standardized, reproducible delivery of nebulized solutions while capturing real-time respiratory waveforms during both natural and suppressed testing conditions.
Experimental procedures evaluated natural reflex cough first, followed by suppressed reflex cough testing after a minimum five-minute interval. In the natural reflex cough condition, participants received randomized presentations of saline control and four capsaicin concentrations: 50, 100, 150, and 200 micromolar across three randomized blocks. Participants were instructed at the start of each block to cough if they felt the need, with at least one minute separating consecutive doses. Following each presentation, participants rated their perceived urge-to-cough using a modified Borg scale from 0 to 10. For suppressed reflex cough testing, capsaicin doses were delivered in ascending concentration across three blocks with interspersed saline, including doses from 50 up to 400 micromolar. Research staff instructed participants before each block to suppress their cough to the best of their ability, continuing until the cough dose-response threshold was reached or the maximum concentration was delivered.
All thirteen participants completed all blocks of natural testing, whereas three individuals completed only two blocks of suppressed testing due to time constraints, fatigue, or temporary capsaicin irritation that resolved after breaks and water. The primary outcome was the C1 dose-response threshold, defined as the lowest capsaicin concentration that elicited a single cough within thirty seconds in two of three trials. The mean capsaicin concentration that induced a cough response was 150 micromolar in both natural and suppressed conditions, with a Wilcoxon signed-rank test confirming no statistically significant difference between conditions. Similarly, the secondary sensory outcome, defined as the lowest concentration eliciting an urge-to-cough in two of three trials, yielded a median threshold of 50 micromolar in both conditions without significant difference. These primary findings demonstrated that individuals with Progressive Supranuclear Palsy were entirely unable to raise their reflexive cough thresholds when instructed to suppress.
Biomechanical assessments of cough motor output revealed that instruction to suppress did not alter the physical execution of reflexive coughing. Comparisons between natural and suppressed reflex cough conditions revealed no significant differences in cough airflow, volume, or timing metrics measured at the lowest effective capsaicin concentration. However, perceptual evaluations revealed a selective divergence in subjective sensory intensity at higher capsaicin exposure. At the 200 micromolar capsaicin dose, participants reported significantly higher urge-to-cough ratings during the suppressed condition than during the natural condition, a difference confirmed to be statistically significant by the Wilcoxon signed-rank test. The study authors suggested that this amplified sensory rating may have resulted from increased cognitive resource allocation, as participants actively focused mental effort on trying to inhibit their cough reflex against a potent irritant. This shows that sensory perception remained robust and sensitive to instructional context even though motor suppression failed.
The observed deficit in reflexive cough suppression reflects disease-related damage to neural circuits responsible for volitional motor planning and sensory integration. Unlike healthy adults and individuals with Parkinson disease who suppress reflexive cough by one to two dose concentrations, participants with Progressive Supranuclear Palsy showed a narrow range of volitional control over cough. This impairment stems from neuropathology affecting key substrates including the supplementary motor area, anterior mid-cingulate cortex, anterior insula, pontomedullary junction, and superior parietal lobe, which Clark and colleagues linked to volitionally modulated oral swallowing deficits. Clinically, impaired cough suppression could serve as a valuable diagnostic red flag to differentiate Progressive Supranuclear Palsy from Parkinson disease. Although capsaicin testing is not widely available in routine clinics, stimuli like citric acid are readily accessible. Despite study limitations including a small sample size of thirteen participants, clinical rather than post-mortem diagnosis, and non-normally distributed data lacking C2 responses, previous findings showing that biofeedback training can increase peak expiratory flow rates suggest that preserved volitional pathways can still be targeted for airway rehabilitation.
Subject of Research: Volitional reflex cough suppression capacity in Progressive Supranuclear Palsy
Article Title: Volitional control capacity for cough modulation in Progressive Supranuclear Palsy
Article References: Mir, M. J., Childers, J., & Wheeler-Hegland, K. (2026). Volitional control capacity for cough modulation in Progressive Supranuclear Palsy. Journal of Rare Diseases, 5(1), Article 114. https://doi.org/10.1007/s44162-026-00259-2
Image Credits: AI Generated
DOI: 10.1007/s44162-026-00259-2
Keywords: Progressive Supranuclear Palsy, Reflex Cough Suppression, Volitional Cough Modulation, Urge-to-Cough, Capsaicin Cough Challenge, Airway Defense, Parkinsonian Disorders, C1 Dose-Response Threshold, Pneumotachograph, Richardson Syndrome, Cortical Modulation, Superior Parietal Lobe, Supplementary Motor Area, Borg Scale, Aspiration Prevention, Respiratory Sensorimotor Function, Peak Expiratory Flow Rate, Differential Diagnosis in Parkinsonism
News Source: Ophelia Keating. (November 16, 2026). Progressive Supranuclear Palsy Impairs Volitional Suppression of Reflexive Cough. Scienmag.



